The objective of this research project is to evaluate the biological effects of long-chain omega-3 supplementation, administered in an optimized, high-purity formulation (EPA:DHA 6:1, \>95% v/v), as an adjunct to standard-of-care treatment in patients with pulmonary arterial hypertension (PAH).
The expected results are confirmation in humans of our preliminary data, namely a beneficial effect on systemic inflammation and pulmonary endothelial dysfunction in PAH. If our hypothesis is confirmed, omega-3s could constitute a complementary nutritional approach to current PAH therapies, subsequently requiring validation through a larger-scale, randomized, controlled study.
Men or women between the ages of 18 and 75;
Idiopathic, hereditary, drug-induced, or anorexigen-induced PAH, or PAH associated with connective tissue disease;
Stable PAH treatment for at least 90 days;
Subjects capable of understanding the objectives and risks associated with the study and of providing dated and signed informed consent;
Patients treated with Omacor®;
Daily consumption of fish oil or fish oil-based dietary supplements (omega-3);
Hypersensitivity or allergy to fish, shellfish, peanuts, soy, corn oil, or coconut oil;
Anticoagulant therapy at therapeutic doses;